Benserazide as a potential novel fetal hemoglobin inducer: an observational study in non-carriers of hemoglobin disorders-Reference-Cited by-同舟云学术

Benserazide as a potential novel fetal hemoglobin inducer: an observational study in non-carriers of hemoglobin disorders

Published:2021-03 Issue: Volume:87 Page:102511
ISSN:1079-9796
Container-title:Blood Cells, Molecules, and Diseases
language:en
Short-container-title:Blood Cells, Molecules, and Diseases

Author:

Santos Marina Erê Hummel Pimenta,Olops Leticia,Vendrame Felipe,Tavares Alvaro Henrique Junqueira,Leonardo Daniela Pinheiro,de Azevedo Paula Christina,Piovesana Luiza Gonzaga,Costa Fernando Ferreira,Fertrin Kleber Yotsumoto

Funder

Fundação de Amparo à Pesquisa do Estado de São Paulo

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Publisher

Elsevier BV

Subject

Cell Biology,Hematology,Molecular Biology,Molecular Medicine

Reference16 articles.

1. Effects of hydroxyurea on F-cells in sickle cell disease and potential impact of a second fetal globin inducer;Dai;Am. J. Hematol.,2017

2. Boosalis MS, Sangerman JI, White GL, et al. Novel inducers of fetal globin identified through high throughput screening (HTS) are active in vivo in anemic baboons and transgenic mice. Wilber AC, ed. PLoS One. 2015;10(12):e0144660. doi:https://doi.org/10.1371/journal.pone.0144660.

3. Seminars in hematology fetal hemoglobin induction by epigenetic drugs;Lavelle;Semin. Hematol.,2019

4. Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders.;Lohani,2018

5. Improved fetal hemoglobin with mTOR inhibitor-based immunosuppression in a kidney transplant recipient with sickle cell disease;Gaudre;Am. J. Transplant.,2017

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Experimental and computational assessment of Antiparkinson Medication effects on meiofauna: Case study of Benserazide and Trihexyphenidyl;Marine Pollution Bulletin;2024-08

2. Current and Future Therapeutics for Treating Patients with Sickle Cell Disease;Cells;2024-05-16

3. CRISPR/Cas9-based gene-editing technology for sickle cell disease;Gene;2023-07

4. The state of the art of fetal hemoglobin-inducing agents;Expert Opinion on Drug Discovery;2022-11-02

5. Pharmacological Induction of Fetal Hemoglobin in β-Thalassemia and Sickle Cell Disease: An Updated Perspective;Pharmaceuticals;2022-06-16